JP5406040B2 - 医薬使用のためのリパーゼ変異体 - Google Patents

医薬使用のためのリパーゼ変異体 Download PDF

Info

Publication number
JP5406040B2
JP5406040B2 JP2009543078A JP2009543078A JP5406040B2 JP 5406040 B2 JP5406040 B2 JP 5406040B2 JP 2009543078 A JP2009543078 A JP 2009543078A JP 2009543078 A JP2009543078 A JP 2009543078A JP 5406040 B2 JP5406040 B2 JP 5406040B2
Authority
JP
Japan
Prior art keywords
lipase
seq
enzyme
amino acids
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009543078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512795A5 (enExample
JP2010512795A (ja
Inventor
スベンセン,アラン
スクヨエット,ミシェル
ヤバー,デビー
レーマン ヒュリング クリステンセン,ラーズ
エスキルセン ラーセン,シグネ
ルンディン,ニーナ
ランサ,マイケル
コリン グレゴリー,ピーター
Original Assignee
ノボザイムス アクティーゼルスカブ
ノボザイムス,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボザイムス アクティーゼルスカブ, ノボザイムス,インコーポレイティド filed Critical ノボザイムス アクティーゼルスカブ
Publication of JP2010512795A publication Critical patent/JP2010512795A/ja
Publication of JP2010512795A5 publication Critical patent/JP2010512795A5/ja
Application granted granted Critical
Publication of JP5406040B2 publication Critical patent/JP5406040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • C12N9/20Triglyceride splitting, e.g. by means of lipase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003Triacylglycerol lipase (3.1.1.3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2009543078A 2006-12-21 2007-12-12 医薬使用のためのリパーゼ変異体 Active JP5406040B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21
US60/871,196 2006-12-21
PCT/US2007/087168 WO2008079685A2 (en) 2006-12-21 2007-12-12 Lipase variants for pharmaceutical use

Publications (3)

Publication Number Publication Date
JP2010512795A JP2010512795A (ja) 2010-04-30
JP2010512795A5 JP2010512795A5 (enExample) 2011-02-03
JP5406040B2 true JP5406040B2 (ja) 2014-02-05

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543078A Active JP5406040B2 (ja) 2006-12-21 2007-12-12 医薬使用のためのリパーゼ変異体

Country Status (16)

Country Link
US (3) US8273348B2 (enExample)
EP (6) EP2455461B1 (enExample)
JP (1) JP5406040B2 (enExample)
KR (1) KR20090101930A (enExample)
CN (2) CN105112386A (enExample)
AR (1) AR064494A1 (enExample)
AU (1) AU2007337150A1 (enExample)
BR (1) BRPI0721103A2 (enExample)
CA (3) CA2961041C (enExample)
IL (1) IL198893A0 (enExample)
MX (1) MX2009006597A (enExample)
NO (1) NO20092729L (enExample)
RU (1) RU2009128067A (enExample)
TW (1) TW200829698A (enExample)
WO (1) WO2008079685A2 (enExample)
ZA (1) ZA200903598B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5032300B2 (ja) 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
EP2278002B1 (en) 2005-07-29 2017-07-12 Abbott Laboratories GmbH Pancreatin with reduced viral content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2008079685A2 (en) * 2006-12-21 2008-07-03 Novozymes A/S Lipase variants for pharmaceutical use
JP2011513539A (ja) * 2008-02-29 2011-04-28 ザ プロクター アンド ギャンブル カンパニー リパーゼを含む洗剤組成物
MX2010009464A (es) 2008-02-29 2010-09-22 Dsm Ip Assets Bv Lipasas con alta especificidad hacia acidos grasos de cadena corta y usos de las mismas.
EP2250258B1 (en) * 2008-02-29 2017-01-04 Novozymes A/S Lipolytic enzyme variant with improved stability and polynucleotides encoding same
CA2782613C (en) 2009-12-09 2016-08-23 The Procter & Gamble Company Fabric and home care products
US20140147895A1 (en) 2011-07-22 2014-05-29 Novozymes A/S Processes for Pretreating Cellulosic Material and Improving Hydrolysis Thereof
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
ES2680145T3 (es) * 2011-12-29 2018-09-04 Novozymes A/S Composiciones detergentes con variantes de lipasa
US9394530B2 (en) * 2012-02-03 2016-07-19 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2013149858A1 (en) 2012-04-02 2013-10-10 Novozymes A/S Lipase variants and polynucleotides encoding same
CA2887898A1 (en) * 2012-10-12 2014-04-17 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
CN115521831A (zh) * 2013-05-14 2022-12-27 诺维信公司 洗涤剂组合物
ES2956266T3 (es) * 2013-07-19 2023-12-18 Danisco Us Inc Composiciones y procedimientos que comprenden una variante de enzima lipolítica
EP3221447A1 (en) * 2014-11-20 2017-09-27 Novozymes A/S Alicyclobacillus variants and polynucleotides encoding same
US10457921B2 (en) 2014-12-05 2019-10-29 Novozymes A/S Lipase variants and polynucleotides encoding same
MX382218B (es) * 2014-12-09 2025-03-13 Novozymes As Variantes de lipasa y polinucleotidos que las codifican.
EP3280818A2 (en) 2015-04-07 2018-02-14 Novozymes A/S Methods for selecting enzymes having lipase activity
EP3317407B1 (en) * 2015-07-01 2021-05-19 Novozymes A/S Methods of reducing odor
US10760037B2 (en) * 2015-07-03 2020-09-01 Novozymes A/S Sulfite compositions
US11326152B2 (en) 2016-07-18 2022-05-10 Novozymes A/S Lipase variants, polynucleotides encoding same and the use thereof
JP7081767B2 (ja) * 2017-01-30 2022-06-07 学校法人日本医科大学 アデノ随伴ウイルス(aav)キャプシドタンパク質の変異体
MX2020003779A (es) * 2017-09-27 2020-08-03 Procter & Gamble Composiciones detergentes que comprenden lipasas.
JP7317811B2 (ja) * 2017-09-27 2023-07-31 ノボザイムス アクティーゼルスカブ リパーゼ変異体及びかかるリパーゼ変異体を含むマイクロカプセル組成物
WO2019154952A1 (en) * 2018-02-08 2019-08-15 Novozymes A/S Lipase variants and compositions thereof
WO2020037100A1 (en) * 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
US12467042B2 (en) * 2020-06-24 2025-11-11 Dermapharm Aktiengesellschaft Lipase enzyme
EP4237552A2 (en) * 2020-10-29 2023-09-06 Novozymes A/S Lipase variants and compositions comprising such lipase variants
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
AU2023272468A1 (en) 2022-05-14 2024-11-14 Novonesis Plant Biosolutions A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
CN119522274A (zh) * 2022-06-24 2025-02-25 诺维信公司 脂肪酶变体和包含这样的脂肪酶变体的组合物
CN120082537A (zh) * 2023-12-01 2025-06-03 青岛蔚蓝生物集团有限公司 一种脂肪酶突变体

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
DK46693D0 (enExample) 1993-04-23 1993-04-23 Novo Nordisk As
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
JP3469234B2 (ja) * 1990-09-13 2003-11-25 ノボザイムス アクティーゼルスカブ リパーゼ変異体
DE69130113T2 (de) 1990-12-05 1999-05-12 Novo Nordisk A/S, Bagsvaerd Proteine mit geänderten epitopen und verfahren zur deren herstellung
ATE169678T1 (de) 1991-05-01 1998-08-15 Novo Nordisk As Stabilisierte enzyme
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
BR9407752A (pt) 1993-10-04 1997-03-04 Novo Nordisk As Preparaçao de enzima aditivo detergente composiçao detergente processo para o tratamento de fibras lignocelulósicas
AU1806795A (en) 1994-02-22 1995-09-04 Novo Nordisk A/S A method of preparing a variant of a lipolytic enzyme
JPH10509324A (ja) 1994-11-24 1998-09-14 ノボ ノルディスク アクティーゼルスカブ 抑制されたアレルゲン性を有するポリペプチドの製造のための方法
AU697440B2 (en) 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
CA2209617C (en) 1995-01-26 2002-05-28 Novo Nordisk A/S Animal feed additives comprising xylanase
WO1997004079A1 (en) 1995-07-14 1997-02-06 Novo Nordisk A/S A modified enzyme with lipolytic activity
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
CN1192780B (zh) 1995-08-11 2010-08-04 诺沃奇梅兹有限公司 新的脂解酶
JP2002510963A (ja) 1997-01-10 2002-04-09 ノボザイムス アクティーゼルスカブ スキンケア用酵素修飾体
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして/又は除去された付着基を有するポリペプチド−ポリマー結合体
JP2002516615A (ja) 1997-06-25 2002-06-04 ノボザイムス アクティーゼルスカブ 変性ポリペプチド
ATE328070T1 (de) * 1998-02-17 2006-06-15 Novozymes As Lipasevariante
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
WO2000022103A1 (en) 1998-10-13 2000-04-20 Novozymes A/S A modified polypeptide with reduced immune response
DE69938435D1 (de) 1998-10-30 2008-05-08 Novozymes As Niedrigallergene Proteinvarianten
CA2348822A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
EP1131416B1 (en) 1998-11-27 2009-09-02 Novozymes A/S Lipolytic enzyme variants
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
TR200102784T2 (tr) 1999-03-17 2002-04-22 Solvay Pharmaceuticals Gmbh Diyabet tedavisi için ilaç
EP1171581A1 (en) * 1999-03-31 2002-01-16 Novozymes A/S Lipase variant
EP2278000A1 (en) * 1999-03-31 2011-01-26 Novozymes A/S Lipase variant
WO2001058276A2 (en) 2000-02-08 2001-08-16 F Hoffmann-La Roche Ag Use of acid-stable proteases in animal feed
WO2001083761A1 (en) 2000-04-28 2001-11-08 Novozymes A/S Laccase mutants
DE60231700D1 (de) * 2001-01-10 2009-05-07 Novozymes As Variante eines lipolytischen enzyms
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
CN1491278A (zh) 2001-02-07 2004-04-21 ŵά�Ź�˾ 脂酶变体
EP1468084A1 (en) * 2002-01-16 2004-10-20 Novozymes A/S Lipolytic enzyme variants and method for their production
JP2007506405A (ja) 2003-02-06 2007-03-22 ノボザイムス アクティーゼルスカブ 糸状菌におけるヒトh鎖抗体の発現
EP2270139B1 (en) * 2003-05-09 2016-07-27 Novozymes A/S Variant lipolytic enzymes
US20060236414A1 (en) 2003-06-19 2006-10-19 Novozymes A/S Proteases and methods for producing them
EP1639102A2 (en) * 2003-06-19 2006-03-29 Novozymes A/S Phospholipase variants
AR047440A1 (es) 2004-01-21 2006-01-18 Novozymes As Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal
JP5032300B2 (ja) 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
DK1809320T3 (da) 2004-10-14 2010-11-15 Cystic Fibrosis Foundation The Præparater indeholdende lipase, protease og amylase til behandling af pankreatisk insufficiens
US20080138856A1 (en) 2005-02-10 2008-06-12 Novozymes A/S Enzymatic Enantioselective Ester or Amide Hydrolysis or Synthesis
KR20080017025A (ko) * 2005-06-24 2008-02-25 노보자임스 에이/에스 약학적 용도의 리파제
MX2007015471A (es) 2005-06-24 2008-04-04 Novozymes As Amilasas para uso farmaceutico.
JP2008546395A (ja) 2005-06-24 2008-12-25 ノボザイムス アクティーゼルスカブ 医薬使用のためのプロテアーゼ
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
CN105296445B (zh) * 2006-01-23 2022-05-10 诺维信公司 脂肪酶变体
CA2635927A1 (en) * 2006-01-23 2007-08-02 The Procter And Gamble Company A composition comprising a lipase and a bleach catalyst
WO2008079685A2 (en) * 2006-12-21 2008-07-03 Novozymes A/S Lipase variants for pharmaceutical use

Also Published As

Publication number Publication date
CA2961041A1 (en) 2008-07-03
EP2455459A2 (en) 2012-05-23
EP2455461A3 (en) 2013-05-29
NO20092729L (no) 2009-09-18
US20100034797A1 (en) 2010-02-11
ZA200903598B (en) 2010-04-28
TW200829698A (en) 2008-07-16
US9029115B2 (en) 2015-05-12
EP2099907A2 (en) 2009-09-16
EP2455462B1 (en) 2016-03-16
EP2455459A3 (en) 2013-04-24
CN105112386A (zh) 2015-12-02
CA3081308A1 (en) 2008-07-03
EP2455461B1 (en) 2016-03-16
EP2455461A2 (en) 2012-05-23
CA2961041C (en) 2020-07-14
EP2261328B1 (en) 2013-11-20
RU2009128067A (ru) 2011-01-27
WO2008079685A3 (en) 2008-11-06
BRPI0721103A2 (pt) 2014-03-04
CN101743308A (zh) 2010-06-16
EP2455462A3 (en) 2013-05-29
CA3081308C (en) 2024-02-20
IL198893A0 (en) 2010-02-17
KR20090101930A (ko) 2009-09-29
AR064494A1 (es) 2009-04-08
EP2455460A2 (en) 2012-05-23
US20150209414A1 (en) 2015-07-30
EP2455459B1 (en) 2016-03-16
US20120308543A1 (en) 2012-12-06
CA2670643C (en) 2017-04-25
EP2455462A2 (en) 2012-05-23
WO2008079685A2 (en) 2008-07-03
US8273348B2 (en) 2012-09-25
US9539311B2 (en) 2017-01-10
EP2261328A1 (en) 2010-12-15
CN101743308B (zh) 2015-09-16
CA2670643A1 (en) 2008-07-03
MX2009006597A (es) 2009-07-02
AU2007337150A1 (en) 2008-07-03
EP2455460A3 (en) 2012-12-26
JP2010512795A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
JP5406040B2 (ja) 医薬使用のためのリパーゼ変異体
US20090047266A1 (en) Lipases for Pharmaceutical Use
JP2008546396A (ja) 薬学的に使用するためのアミラーゼ
US8455235B2 (en) Protease variants for pharmaceutical use
AU2013203500B2 (en) Lipase variants for pharmaceutical use
AU2013200626B2 (en) Lipase variants for pharmaceutical use
HK1141553A (en) Lipase variants for pharmaceutical use
HK1113174A (en) Lipases for pharmaceutical use
HK1145697A (en) Protease variants for pharmaceutical use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131031

R150 Certificate of patent or registration of utility model

Ref document number: 5406040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250